This segment focuses on the development of oncolytic viral immunotherapies, leveraging modified viruses to selectively infect and destroy cancer cells while stimulating an immune response against the tumor. Research & Development activities include engineering herpes simplex virus type 1 (oHSV) and other viral vectors to enhance their oncolytic activity and immunogenicity. Technologies used involve genetic engineering, virology, and immunology. The therapeutic areas targeted are various solid tumors, including cutaneous, subcutaneous, and metastatic nodal tumors. The goal is to improve patient outcomes by providing targeted and effective cancer treatments with minimal side effects. Market positioning involves competing with other immunotherapy approaches by offering a unique mechanism of action. Future opportunities include expanding the pipeline with novel viral vectors and combination therapies. Clinical trials are essential for evaluating the safety and efficacy of these therapies.

This segment is dedicated to the development of intravenously administered, self-amplifying RNA medicines for cancer treatment. Research & Development efforts are focused on creating novel lipid nanoparticle (LNP) formulations for mRNA drug candidates, enhancing their delivery and efficacy. Technologies used include RNA engineering, lipid chemistry, and drug delivery systems. The therapeutic areas targeted are a broad range of cancers, with the aim of providing systemic treatment options. The patient impact is to offer more accessible and effective RNA-based therapies. Market positioning involves competing with other RNA therapeutics companies by focusing on self-amplifying RNA technology. Future opportunities include expanding the pipeline with new RNA constructs and delivery methods. Partnerships and collaborations, such as the one with Daewoong Pharmaceutical, are crucial for advancing this segment.